Please login to the form below
Digital intelligence blog
Pharma insight on digital marketing, social media, mobile apps, online video, websites and interactive healthcare tools
J&J collaborates on consumer health device accelerator
Partners with Shenzhen-based investor firm HAX
Johnson & Johnson is working with Shenzhen-based investor firm HAX on an accelerator programme for novel consumer health devices.
The firm's Johnson & Johnson Innovation arm will work with HAX on supporting start-ups that are developing technologies in areas such as skin care, baby care and wound care.
The world's largest hardware accelerator with bases in Silicon Valley and south east China, HAX has a specific health track within its Shenzhen hardware accelerator.
Companies that have successfully applied to its spring 2017 call for entries and are then co-selected by HAX and J&J will receive mentorship in business development and commercialization from Johnson & Johnson Innovation executives.
They will also, HAX said, learn how to align their products with Johnson & Johnson's consumer health care portfolio.
COVID-19 Updates and Daily News
Featured jobs
- Account Director, Medical Communications & Events
-
£50 - 65, 000 according to skills and experience benefits
-
Account Manager
-
£Competitive Salary
- Brand Manager - Medium Global Pharma Company
-
£Competitive Financial Package
-
Senior External Communications Lead
-
£Competitive Salary
-
Senior Account Manager
-
Salary TBC
- Group Director of Medical Affairs and Scientific Strategy, Medic...
-
Substantial six figure package
-
Account Director
-
£Competitive Salary
-
Account Director – UK Office
-
Excellent salary and benefits
-
Account Manager (PR)
-
Great Benefits
- Senior Medical Writer or Lead Medical Writer
-
£Competitive Salary
- AbbVie suspends Kaletra patent rights as COVID-19 drug trials advance
- FDA grants emergency authorisation to chloroquine for COVID-19
- UPDATED: Gilead drops remdesivir’s orphan drug designation
- Moderna and GSK advance coronavirus vaccine candidates
- Germany's coronavirus infections climb but deaths remain low
- Sanofi, Regeneron launch trials of arthritis drug Kevzara for COVID-19
- OSE lung cancer vaccine clears phase 3 hurdle, but COVID-19 stalls programme
- Clinical trial of Gilead’s coronavirus hopeful remdesivir begins in UK
- UK government reveals only 2,000 key NHS staff have been tested for coronavirus
- Today’s reality: how to make social distancing work in medcomms
- Q&A: Kate Paxton
- Lilly cuts deal with UK’s Sitryx for autoimmune disease drugs
PMHub
Onyx Health Ltd
Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national...
Latest intelligence
- Delivering true value: what does it mean for KAM in cancer care?
- Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...
- Pharma funding and M&A in 2020
- Why pharma M&A has continually bucked the trend...
- Behaviour change through medical education: How can we turn aspiration into reality?
- Practical, evidence-based insights into a CME process that aims to effect measurable behaviour change...
Quick links
Infographics
